Evidence map›Paper›PMID 34654574›Full record

ArticleGynecologic oncology2021

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].

Kimberly Levinson, Anna L Beavis, Christopher Purdy, Anne F Rositch, Akila Viswanathan, Aaron H Wolfson, Michael G Kelly, Krishnansu S Tewari, Leah McNally, Saketh R Guntupalli and 11 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Kimberly LevinsonJohns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: klevins1@jhmi.edu.
Anna L BeavisJohns Hopkins University School of Medicine, Baltimore, MD, United States.
Christopher PurdyNRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Anne F RositchJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States.
Akila ViswanathanJohns Hopkins University School of Medicine, Baltimore, MD, United States.
Aaron H WolfsonSylvester Comprehensive Cancer Center, Miami, FL, United States.
Michael G KellyWake Forest Baptist Medical Center, Winston-Salem, NC, United States.
Krishnansu S TewariUniversity of California Irvine, Orange, CA, United States.
Leah McNallyDuke Cancer Institute, Durham, NC, United States.
Saketh R GuntupalliUniversity of Colorado Anschutz, Aurora, CO, United States.
Omar RagabKeck School of Medicine of USC, Los Angeles, CA, United States.
Yi-Chun LeeSUNY Health Science Center at Brooklyn, Brooklyn, NY, United States.
David S MillerUniversity of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9032, United States.
Warner K HuhUniversity of Alabama at Birmingham, Birmingham, AL, United States.
Kelly J WilkinsonUniversity of Mississippi Medical Center, Jackson, MS, United States.
Nicola M SpirtosWomen's Cancer Center, Las Vegas, NV, United States.
Linda Van LeUniversity of North Carolina School of Medicine, Chapel Hill, NC, United States.
Yovanni CasablancaWalter Reed National Medical Center, Bethesda, MD, United States.
Laura L HolmanUniversity of Oklahoma Health Sciences Center, Stephenson Cancer Center, 800 Northeast Tenth St., Oklahoma City, OK, United States.
Steven E WaggonerCase Western Reserve University, Cleveland, OH, United States.
Amanda N FaderJohns Hopkins University School of Medicine, Baltimore, MD, United States.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4M
Network Lead Academic Participating Site Grant from the Roswell Park Cancer InstituteUG1CA233191 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI LELE, SHASHIKANT, LEVINE, ELLIS G · 2019 to 2025
$3.1M
NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA233191
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34654574
PMCPMC8627434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.